* Medarex Inc., of Annandale, N.J., reported Phase I clinical trial results show MDX-33, its autoimmune disease product, to be well tolerated at a dose capable of "turning off" an immune function that may be implicated in autoimmune diseases such as idiopathic thrombocytopenic purpura, rheumatoid arthritis and lupus erythematosus.

* Neurex Corp., of Menlo Park, Calif., reported that Medtronic Inc., of Minneapolis, has recently made a Securities and Exchange Commission filing indicating that Medtronic intends to sell up to 221,000 shares of Neurex common stock over the next three months. As of June 27, 1997, Medtronic owned approximately 1.8 million shares of Neurex common stock, which represents 8.2 percent of Neurex's outstanding shares, along with warrants to purchase 669,646 shares of common stock.